Should I get liquid biopsy or tissue biopsy for HER2-Low Breast Cancer

Liquid Biopsy vs. Tissue Biopsy for HER2-Low Breast Cancer

This is an excellent question, and the answer depends on your specific clinical situation. Let me break down how doctors think about this decision.

Understanding Your Options

Tissue Biopsy (Traditional Approach):

• Involves removing actual tumor cells through a needle or surgical procedure
• Provides comprehensive genetic information about your cancer
• Considered the gold standard for initial diagnosis and molecular profiling
• Required to definitively diagnose HER2-low status

Liquid Biopsy (Blood Test):

• Analyzes circulating tumor DNA (ctDNA) or tumor cells floating in your blood
• Less invasive, no surgical procedure needed
• Can be repeated more frequently to monitor treatment response
• Increasingly useful for tracking disease progression and detecting resistance mutations

How Doctors Typically Approach This Decision

According to the CancerPatientLab webinar "Accessing the Latest Developments in Liquid Biopsies," liquid biopsies are particularly valuable because they are less invasive than traditional tissue biopsies, especially if you are medically fragile or cannot undergo surgical procedures. They offer minimal discomfort and can increase testing frequency.

However, the webinar experts emphasize that tissue-based testing and liquid biopsy work together synergistically. As one expert noted: "It's really important to use as many different tests as possible. Education is power. Knowledge is power. The more different platforms we have to look at, the better."

The Clinical Framework for HER2-Low Breast Cancer

For your specific situation, here's what typically happens:

Initial Diagnosis Phase:

• Tissue biopsy is usually necessary first to confirm HER2-low status and identify other important biomarkers (like hormone receptor status, tumor mutational burden)
• This comprehensive profiling guides your initial treatment decisions

Monitoring & Treatment Response Phase:

• Liquid biopsies become increasingly valuable for tracking how well treatment is working
• They can detect resistance mutations before they become clinically apparent
• This helps your doctor know when it might be time to change therapeutic approaches

Important Considerations for Your Decision

According to the webinar guidance, when deciding between these tests, consider:

1. Clinical Evidence: Look for providers with robust published research for breast cancer specifically
2. Test Specificity: Evaluate the test's performance in terms of sensitivity and specificity for your particular needs
3. Regulatory Approvals: Prefer providers with FDA clearance (tests like Guardant360 CDx and FoundationOne Liquid CDx are FDA-approved for comprehensive cfDNA analysis)
4. Insurance Coverage: Verify if the test is reimbursed by your insurance
5. Turnaround Time: Consider how quickly you need results

Questions to Ask Your Oncology Team

Since your specific situation requires your doctor's evaluation, here are targeted questions:

1. "Do I need tissue biopsy first to confirm my HER2-low status and complete molecular profiling, or has this already been done?"

2. "Once my initial diagnosis is established, would a liquid biopsy be helpful for monitoring my treatment response?"

3. "Which liquid biopsy test would you recommend, and is it FDA-approved for breast cancer monitoring?"

4. "How frequently would you want to repeat testing, and does a liquid biopsy make sense given how often monitoring is needed?"

5. "Are there any barriers to accessing liquid biopsy testing—such as insurance coverage or availability—that we should discuss?"

The Bottom Line

For HER2-low breast cancer, tissue biopsy is typically needed initially to establish your diagnosis and complete comprehensive molecular profiling. However, liquid biopsy becomes increasingly valuable during treatment for monitoring response and detecting early signs of resistance.

Rather than choosing one over the other, your oncologist will likely recommend using both strategically—tissue biopsy for diagnosis, liquid biopsy for ongoing monitoring. This complementary approach gives you and your care team the most complete picture of your cancer's behavior.

Your oncologist will determine the most appropriate approach for YOUR case based on your complete clinical picture, including whether tissue samples are already available, your treatment plan, and your individual circumstances.

---

Sources Referenced:

• CancerPatientLab Webinar: "Accessing the Latest Developments in Liquid Biopsies" (Lauren Leiman and Jenn Dickey)
• CancerPatientLab Webinar: "Testing Your RNA with Liquid Biopsies" (Alex Rolland)
• CancerPatientLab Webinar: "The BostonGene Tumor Portrait Report and How to Access It" (Michael Hensley and Michelle Lanman)

This information is for educational purposes only. Always consult your healthcare team for personalized medical advice and decisions.